4D Molecular Therapeutics announced positive 52-week data from the Phase 2b study of 4D-150, focusing on its effectiveness for treating wet age-related macular degeneration. CEO David Kirn highlighted the potential of 4D-150 to be a foundational therapy for vascular retinal diseases.
Company Information
Company
4D Molecular Therapeutics
Location
Emeryville, California, United States
About
4DMT is a late-stage biotechnology company developing durable, disease-targeted genetic medicines designed to transform treatment paradigms and deliver long-lasting benefits to patients. Its lead candidate, 4D-150, aims to become a backbone therapy for blinding retinal vascular diseases by providing multi-year sustained delivery of anti-VEGF agents through a single intravitreal injection, with Phase 3 development underway for wet age-related macular degeneration and a second indication in diabetic macular edema. The company’s second candidate, 4D-710, is the first known genetic medicine to achieve successful aerosol-based delivery and expression of the CFTR transgene in the lungs of people with cystic fibrosis.
Fundz sees it the moment 4D Molecular Therapeutics ships something new, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
EmeryvilleBiotechnologyHealth CareMedicalGeneticsTherapeutics